Head-To-Head Comparison Of Subcutaneous Abatacept Versus Adalimumab On Background Methotrexate In RA: Blinded Two Year Results From The Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjectswith Background Methotrexate) study

被引：0
|
作者：
Weinblatt, Michael E. [1 ]
Schiff, Michael H. [2 ]
Valente, Robert [3 ]
van der Heijde, Desiree M. [4 ]
Citera, Gustavo [5 ]
Elegbe, Ayanbola [6 ]
Maldonado, Michael A. [6 ]
Fleischmann, Roy M. [7 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Univ Colorado, Denver, CO 80202 USA
[3] Arthrit Ctr Nebraska, Lincoln, NE USA
[4] Leiden Univ, Med Ctr, Leiden, Netherlands
[5] Inst Rehabil Psicofis, Buenos Aires, DF, Argentina
[6] Bristol Myers Squibb Co, Princeton, NJ USA
[7] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2326
引用
收藏
页码：S991 / S992
页数：2
相关论文
共 47 条
  • [31] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
    Smolen, Josef S.
    Burmester, Gerd-Ruediger
    Combe, Bernard
    Curtis, Jeffrey R.
    Hall, Stephen
    Haraoui, Boulos
    van Vollenhoven, Ronald
    Cioffi, Christopher
    Ecoffet, Cecile
    Gervitz, Leon
    Ionescu, Lucian
    Peterson, Luke
    Fleischmann, Roy
    [J]. LANCET, 2016, 388 (10061): : 2763 - 2774
  • [32] A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda M.
    Leage, Soyi Liu
    Pillai, Sreekumar G.
    Mease, Philip
    [J]. INTERNAL MEDICINE JOURNAL, 2020, 50 : 17 - 17
  • [33] A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor study
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Mease, Philip
    Bessette, Louis
    [J]. JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1042 - 1042
  • [34] A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAiVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
    Chaudhury, Sukanya
    Gellett, Amanda M.
    Hojnik, Maja
    Leage, Soyi Liu
    Li, Lingnan
    Mease, Philip
    Nash, Peter
    Pillai, Sreekumar G.
    Schulze-Koops, Hendrik
    Smolen, Josef
    Tahir, Hasan
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 125 - 125
  • [35] A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Mease, Philip J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [36] Real-World Experience with Tofacitinib Versus Adalimumab and Etanercept in Biologic-Naive Patients with RA Previously Treated with Methotrexate: Data from a US Administrative Healthcare Insurance Claims Database
    Smith, Tim
    Harnett, James
    Gruben, David
    Chen, Connie
    Agarwal, Ekta
    Woolcott, John
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [37] SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY
    Mcinnes, I.
    Behrens, F.
    Mease, P. J.
    Kavanaugh, A.
    Ritchlin, C. T.
    Nash, P.
    Gratacos-Masmitja, J.
    Goupille, P.
    Korotaeva, T.
    Gottlieb, A. B.
    Martin, R.
    Ding, K.
    Pellet, P.
    Mpofu, S.
    Pricop, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 142 - 143
  • [38] HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA
    Rigby, William
    Buckner, Jane H.
    Bridges, S. Louis, Jr.
    Nys, Marleen
    Gao, Sheng
    Polinsky, Martin
    Ray, Neelanjana
    Bykerk, Vivian
    [J]. ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [39] HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA
    William Rigby
    Jane H. Buckner
    S. Louis Bridges
    Marleen Nys
    Sheng Gao
    Martin Polinsky
    Neelanjana Ray
    Vivian Bykerk
    [J]. Arthritis Research & Therapy, 23
  • [40] Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis
    Mease, Philip
    Smolen, Josef
    Kavanaugh, Arthur
    Nash, Peter
    Gallo, Gaia
    Liu-Leage, Soyi
    Sapin, Christophe
    Genovese, Mark
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345